I think incremental 1 month extra data wont mean much for the stock.( even though I would want to hear it)
But an announcement that we are now officially a phase 3 company by handing over to Pfizer would mean analysts would have to revise their models to account for being a phase 3 and not a phase 1 company. Also makes the company "less risky" and many institutions wont invest till a product hits phase 3 because of the high risk of phase 1/2 failures ( see Diabetic neuropathy and HIV and IVPRP times 3)
We seem to lumped into the phase 1 market cap companies @ 1B
phase 3 get $2b+